AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) ...

AtaiBeckley Inc. (NASDAQ:ATAI) earns a place on our list of the top 10 stocks under $5 that could triple. Analysts are ...

AtaiBeckley (NasdaqGM:ATAI) reported positive, peer reviewed Phase 2a results for its lead psychedelic drug BPL-003 in treatment resistant depression. The company received supportive FDA feedback for ...

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

AtaiBeckley Inc (NASDAQ:ATAI) is among the best NASDAQ penny stocks to buy according to analysts. On February 26, AtaiBeckley Inc (NASDAQ:ATAI) reported topline results from a Phase 2a trial of its ...

After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure ...

AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more ...

That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is atai Life Sciences N.V. (ATAI) one of those stocks right now? By taking a look at ...

The biotech earned an important fast-track review designation from a major regulator. This should speed the development (and potentially, commercialization) of one of its investigational treatments.